Search Browse Earnings

ImmunityBio, Inc.

Nasdaq:IBRX

Biological Products, (No Diagnostic Substances)·SAN DIEGO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

ImmunityBio, Inc. — SlamSEC

Revenue

$622,000

+159.2% YoY

FY 2025

Adj. EBITDA

-$343.7M

-55263.3% margin

FY 2025

Net Income

-$583.2M

-93761.4% margin

FY 2025

EPS (Diluted)

-$1.15

FY 2025

Stock Price

$8.65

-3.4%

2026-03-06

52W Range

$1.83 – $12.43

P/E Ratio

-7.5x

Market Cap

$8.9B

Cash

$265.5M

FY 2025

Total Debt

$1.2M

FY 2025

Net Cash

$264.2M

FY 2025

Enterprise Value

$8.6B

Debt / EBITDA

0.8x

FY 2025

EV / EBITDA

-25.1x

Employees

—

CEO

Adcock Richard

CFO

Sachs David C.